Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
Current medical research and opinion（2023）
摘要
66% of patients who receive crizanlizumab receive at least 4 doses within 6-months. The low median number of gap days suggests high adherence.
更多查看译文
关键词
Crizanlizumab,sickle cell disease
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要